Sodium-Glucose Cotransporter 2 Inhibitors Work as a "Regulator" of Autophagic Activity in Overnutrition Diseases
Several large clinical trials have shown renal and cardioprotective effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors in diabetes patients, and the protective mechanisms need to be elucidated. There have been accumulating studies which report that SGLT2 inhibitors ameliorate autophagy def...
Saved in:
Main Authors: | Kazuhiko Fukushima (Author), Shinji Kitamura (Author), Kenji Tsuji (Author), Jun Wada (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
by: Jun Tang, et al.
Published: (2022) -
Inhibitors of sodium-glucose cotransporter 2: risk of ketoacidosis
by: T. M. Bukatina, et al.
Published: (2018) -
Bibliometric and visualized analysis of sodium-Glucose cotransporter 2 inhibitors
by: He Sun, et al.
Published: (2023) -
Bibliometric Study of Sodium Glucose Cotransporter 2 Inhibitors in Cardiovascular Research
by: Lu Chen, et al.
Published: (2020) -
Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review
by: Thahesh Tharmaraja, et al.
Published: (2022)